







# Our pipeline

Project	Description	Indications	Partners	Pre-clinical	Phase 1	Phase 2	Phase 3	Filing	Regions
Delgocitinib <sup>1</sup>	Topical pan-JAK inhibitor	Chronic Hand Eczema	 SHIONOGI	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	Global
		Chronic Hand Eczema (adolescents)		<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	Global
		Lichen Sclerosus		<div></div>	<div></div>	<div></div>	<div></div>		Global
		Palmoplantar Pustulosis		<div></div>	<div></div>	<div></div>			Global
Tralokinumab <sup>2</sup>	Anti-IL-13 monoclonal antibody	Atopic Dermatitis (Pediatrics)	 AstraZeneca	<div></div>	<div></div>	<div></div>	<div></div>		Global
Spesolimab <sup>3</sup>	Anti-IL-36 R Monoclonal antibody	Pyoderma Gangrenosum	 Boehringer Ingelheim	<div></div>	<div></div>	<div></div>	<div></div>		Global
Calcipotriol and betamethasone dipropionate <sup>4</sup>	Fixed-Dose Combination	Plaque Psoriasis		<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	China <sup>2</sup>
Temtokibart	Anti-IL-22RA1 monoclonal antibody	Atopic Dermatitis	 argenx	<div></div>	<div></div>	<div></div>			Global
IL-1RAcP	Anti-IL-1RAcP monoclonal antibody	Inflammatory skin diseases	 morphosys	<div></div>	<div></div>				Global
STAT6 <sup>5</sup>	Oral program	Inflammatory skin diseases	 GILEAD	<div></div>					Global
Topical STAT6 <sup>6</sup>	Topical program	Inflammatory skin diseases		<div></div>					Global



<sup>1</sup> Approved in the EU, US, UK, Australia, South Korea, Canada, Switzerland and the UAE for Chronic Hand Eczema  
<sup>2</sup> Approved in the EU and U.S. and additional regions for atopic dermatitis.  
<sup>3</sup> Approved in the EU and U.S. and additional regions for Generalized Pustular Psoriasis. LEO Pharma in-licensed Spesolimab from Boehringer Ingelheim on September 30, 2025.  
<sup>4</sup> Approved in the EU and U.S. and additional regions for plaque psoriasis.  
<sup>5</sup> Partnership announced 11 January 2025: Gilead controls the global rights to oral STAT6 program and are in full control of the clinical development. LEO Pharma will have the option to co-commercialize oral programs for dermatology ex-US.  
<sup>6</sup> LEO Pharma holds an exclusive license from Gilead for STAT6 topical products in dermatology.